GSK signals confidence with robust Q2 as specialty medicines surge
Operating profit up 33% as strong product mix and R&D drive gains GSK Plc reported another solid quarter in Q2 2025, underscoring its trajectory toward the top end of its full-year guidance. Bolstered by strong growth in Specialty Medicines and Vaccines, the British pharmaceutical giant posted total revenues of £8.0 billion, up 6% at constant…